Stay tuned and follow the latest developments and news in Molecular Oncology.
The scientific team of GeneKor had a strong presence at the 31st Hellenic Congress of Clinical Oncology, held in Athens from April 9–12, 2025. Our team participated with 10 scientific presentations, including 6 oral presentations by our scientists.
Oral Presentations:
“Counselling of women with hereditary predisposition to endometrial and ovarian cancer.”
Her presentation focused on counseling women with a hereditary predisposition to endometrial and ovarian cancer. The importance of genetic counseling, both before and after testing, was emphasized to ensure proper understanding and evaluation of results. Case studies were presented, along with the significance of selecting the appropriate multigene panel through Next Generation Sequencing (NGS) for effective identification of individuals at genetic risk.
“Detailed validation of an NGS panel of 1021 genes for comprehensive molecular profiling of tumors in tissue and liquid biopsy samples.”
Her presentation highlighted the importance of using large gene panels for oncology patients. It stressed the need for validation of each methodology to ensure result reliability, and also the clinical value of calculating biomarkers such as TMB, MSI, and HRD for patient management.
“Real-world data analysis in patients with ovarian cancer who underwent immunohistochemical determination of FOLR1 (FRα).”
Immunohistochemical expression of folate receptor protein 1 (FOLR1/Fra) is a predictive biomarker for targeted therapy with the mirvetuximab soravtansine-gynx drug-antibody conjugate in patients with platinum-containing epithelial ovarian cancer.
The aim of our study was to investigate the immunohistochemical expression of FRα in patients with ovarian carcinoma.
In 138 patients with ovarian carcinoma who underwent FRα immunohistochemical testing between September 2024 and January 2025, 24% (33/138) positivity was observed, whereas in patients with high-grade malignant serous carcinoma the positivity rate was 31.3% (31/33).
The findings of the present study suggest that a significant proportion of ovarian cancer patients now have the option of receiving targeted therapy, which offers better overall survival and a longer recurrence-free interval compared to previously available treatment options.
“The utility of multigene analysis in the classification and clinical management of patients with central nervous system tumors.”
The study included 112 CNS tumor samples and aimed to assess the clinical utility of multigene analysis in tumor classification. A 1021-gene panel (prime panel) was used, and findings were correlated with histological results. Key findings included:
“Clinical and diagnostic value of genetic testing in patients with cancer syndromes regardless of age at diagnosis.”
Her presentation highlighted the significance of multigene testing in cancer syndrome patients, regardless of age or family history. Based on GeneKor data, among ~3,500 breast and ovarian cancer cases, the positivity rate increases when broader panels are used rather than testing limited to BRCA1/2. Moreover, in ~6,500 breast cancer cases, the positivity rate remained high even in patients diagnosed over the age of 50.
“Detection of ESR1 and PIK3CA gene variants in breast cancer using liquid biopsy: a step toward personalized medicine.”
This study analysed 1,011 breast cancer patient samples using liquid biopsy. Results highlighted the importance of liquid biopsy in identifying new therapeutic strategies, especially in hormone receptor-positive breast cancer patients who developed resistance to hormone therapy due to mutations in ESR1 and PIK3CA.
Our participation in the conference confirms GeneKor’s scientific excellence and its active contribution to advancing personalised medicine and innovation in oncology.
